



## Rajasthan Medical Services Corporation Limited

Gandhi Block, Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur-302005 (Raj.)

Phone No: 0141-2228066 , 2228064 Fax No. 0141-2228065 Website: www.rmsc.nic.in

CIN:U24232RJ2011SGC035067 E\_mail : edprocurement@gmail.com, and rmse@nic.in

Ref. No.:- F.02(158)/RMSC/PROCUREMENT/DRUG/NIB-08/2015/ 1257 Dated: 02-09-2015

### Corrigendum - 1


**Subject:- Amended technical specifications and other conditions of bid document**  
**For the NIB Ref. No. F.02(158)/RMSC/PROCUREMENT/DRUG/NIB-08/2015/1069**  
**Dated:07.08.2015 (Technical bid opening due on dated - 16.09.2015)**

Ref. - Pre bid meeting dated 17.08.2015

S. No	Existing condition / technical specification/Packing Unit/Quantity (clause no.)	Amended condition / technical specification/ Packing Unit/Quantity.																					
1.	<b>Annexure VIII and BoQ</b> <table border="1"> <thead> <tr> <th>S. No</th> <th>Code No.</th> <th>Name of item with specification</th> <th>Shelf Life</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>311</td> <td>Atracurium Injection 10 mg/ml</td> <td>24</td> </tr> </tbody> </table>	S. No	Code No.	Name of item with specification	Shelf Life	1.	311	Atracurium Injection 10 mg/ml	24	<b>Annexure VIII and BoQ</b> <table border="1"> <thead> <tr> <th>S. No</th> <th>Code No.</th> <th>Name of item with specification</th> <th>Amended Shelf Life</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>311</td> <td>Atracurium Injection 10 mg/ml</td> <td>18</td> </tr> </tbody> </table>	S. No	Code No.	Name of item with specification	Amended Shelf Life	1.	311	Atracurium Injection 10 mg/ml	18					
S. No	Code No.	Name of item with specification	Shelf Life																				
1.	311	Atracurium Injection 10 mg/ml	24																				
S. No	Code No.	Name of item with specification	Amended Shelf Life																				
1.	311	Atracurium Injection 10 mg/ml	18																				
2.	<b>Annexure VIII and BoQ</b> <table border="1"> <thead> <tr> <th>S. No</th> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>196</td> <td>Glyceryl Trinitrate Tablets IP 2.6 mg</td> </tr> </tbody> </table>	S. No	Code No.	Name of item with specification	1.	196	Glyceryl Trinitrate Tablets IP 2.6 mg	<b>Annexure VIII and BoQ</b> <table border="1"> <thead> <tr> <th>S. No</th> <th>Amended Code No.</th> <th>Amended Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>650</td> <td>Glyceryl Trinitrate Tablets 2.6 mg Controlled release Tablet</td> </tr> </tbody> </table>	S. No	Amended Code No.	Amended Name of item with specification	1.	650	Glyceryl Trinitrate Tablets 2.6 mg Controlled release Tablet									
S. No	Code No.	Name of item with specification																					
1.	196	Glyceryl Trinitrate Tablets IP 2.6 mg																					
S. No	Amended Code No.	Amended Name of item with specification																					
1.	650	Glyceryl Trinitrate Tablets 2.6 mg Controlled release Tablet																					
3.	<b>Clause 2(c) ELIGIBILITY CRITERIA</b> <b>Clause 5 (i) (j) TECHNICAL BID</b> <b>Annexure-XV Ref. Clause No. 2 (c)</b> <table border="1"> <thead> <tr> <th>S. No.</th> <th>Code No.</th> <th>Name of Item</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>639</td> <td>Oseltamivir Capsule IP 75 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 75 mg]</td> </tr> <tr> <td>2.</td> <td>640</td> <td>Oseltamivir Capsule IP 45 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 45 mg]</td> </tr> <tr> <td>3.</td> <td>641</td> <td>Oseltamivir Capsule IP 30 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 30 mg]</td> </tr> <tr> <td>4.</td> <td>642</td> <td>Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml. [Each ml contains 12 mg Oseltamivir base after reconstitution]</td> </tr> <tr> <td>5.</td> <td>390</td> <td>Ferrous Sulphate and Folic Acid Tab IP Each film coated Tab. Containing Dried Ferrous Sulphate IP-equivalent to 100mg Elemental Iron and Folic Acid IP 0.5mg</td> </tr> <tr> <td>6.</td> <td>391</td> <td>Ferrous Sulphate with Folic Acid Tab. (Paediatric) IP Each film coated Tab. Containing Dried Ferrous Sulphate IP-equivalent to 20mg Elemental Iron and Folic Acid IP 100 mcg.</td> </tr> </tbody> </table>	S. No.	Code No.	Name of Item	1.	639	Oseltamivir Capsule IP 75 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 75 mg]	2.	640	Oseltamivir Capsule IP 45 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 45 mg]	3.	641	Oseltamivir Capsule IP 30 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 30 mg]	4.	642	Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml. [Each ml contains 12 mg Oseltamivir base after reconstitution]	5.	390	Ferrous Sulphate and Folic Acid Tab IP Each film coated Tab. Containing Dried Ferrous Sulphate IP-equivalent to 100mg Elemental Iron and Folic Acid IP 0.5mg	6.	391	Ferrous Sulphate with Folic Acid Tab. (Paediatric) IP Each film coated Tab. Containing Dried Ferrous Sulphate IP-equivalent to 20mg Elemental Iron and Folic Acid IP 100 mcg.	<b>Clause 2(c) ELIGIBILITY CRITERIA</b> <b>Clause 5 (i) (j) TECHNICAL BID</b> <b>Annexure-XV Ref. Clause No. 2 (c)</b> <b>In the existing condition in the clause, it is relaxed as per following:-</b> <ol style="list-style-type: none"> <li><b>For Item code 639, 640, 641 and 642 -</b> Market Standing Certificate of two year acceptable.</li> <li><b>For Item code 639, 640, 641 and 642 -</b> In performance statement (Annexure XV) the bidder should have manufactured at least total 3 commercial batches of the quoted drug in the last 3 years. [2011-2012, 2012-13, 2013-14 or 2012-13, 2013-14, 2014-15]</li> <li><b>For Item code 390 -</b> Tenderer should have at least 3 years Market Standing as a manufacturer/importer for Ferrous Sulphate and Folic Acid Tab IP - Containing Dried Ferrous Sulphate IP-equivalent to 100mg Elemental Iron and Folic Acid IP 0.5mg. Market standing of sugar coated tablet with same composition is also acceptable. However, the firm has to submit with tender, the product permission issued from the Licensing Authority as per RMSC tender specifications.</li> </ol>
S. No.	Code No.	Name of Item																					
1.	639	Oseltamivir Capsule IP 75 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 75 mg]																					
2.	640	Oseltamivir Capsule IP 45 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 45 mg]																					
3.	641	Oseltamivir Capsule IP 30 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 30 mg]																					
4.	642	Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml. [Each ml contains 12 mg Oseltamivir base after reconstitution]																					
5.	390	Ferrous Sulphate and Folic Acid Tab IP Each film coated Tab. Containing Dried Ferrous Sulphate IP-equivalent to 100mg Elemental Iron and Folic Acid IP 0.5mg																					
6.	391	Ferrous Sulphate with Folic Acid Tab. (Paediatric) IP Each film coated Tab. Containing Dried Ferrous Sulphate IP-equivalent to 20mg Elemental Iron and Folic Acid IP 100 mcg.																					

		<p><b>For Item code 391</b> - Tenderer should have at least 3 years Market Standing as a manufacturer/importer for Ferrous Sulphate with Folic Acid Tab. (Paediatric) IP - Containing Dried Ferrous Sulphate IP- equivalent to 20mg Elemental Iron and Folic Acid IP 100 mcg. Market standing of sugar coated tablet with same composition is also acceptable.</p> <p>However, the firm has to submit with tender, the product permission issued from the Licensing Authority as per RMSC tender specifications.</p>
4.	Clause 19(2):-	<p><b>Clause 19(2):- Add the following</b>  The supplier shall replace the stock of NOSQ goods with fresh goods upon intimation to do so by the ordering authority</p>

Rest terms and conditions will remain the same.

  
**Executive Director (Proc.)**  
**RMSC**





